Advertisement
UK markets close in 1 hour 58 minutes
  • FTSE 100

    7,963.08
    +31.10 (+0.39%)
     
  • FTSE 250

    19,882.64
    +71.98 (+0.36%)
     
  • AIM

    743.99
    +1.88 (+0.25%)
     
  • GBP/EUR

    1.1696
    +0.0027 (+0.23%)
     
  • GBP/USD

    1.2642
    +0.0004 (+0.03%)
     
  • Bitcoin GBP

    56,241.96
    +994.20 (+1.80%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,250.17
    +1.68 (+0.03%)
     
  • DOW

    39,728.71
    -31.37 (-0.08%)
     
  • CRUDE OIL

    82.37
    +1.02 (+1.25%)
     
  • GOLD FUTURES

    2,227.80
    +15.10 (+0.68%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,496.61
    +19.52 (+0.11%)
     
  • CAC 40

    8,218.43
    +13.62 (+0.17%)
     

Supernus Pharmaceuticals Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

Supernus Pharmaceuticals (NASDAQ:SUPN) Third Quarter 2022 Results

Key Financial Results

  • Revenue: US$177.4m (up 20% from 3Q 2021).

  • Net income: US$1.75m (down 92% from 3Q 2021).

  • Profit margin: 1.0% (down from 14% in 3Q 2021).

  • EPS: US$0.033 (down from US$0.41 in 3Q 2021).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Supernus Pharmaceuticals Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) missed analyst estimates by 92%.

Looking ahead, revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Pharmaceuticals industry in the US.

ADVERTISEMENT

Performance of the American Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with Supernus Pharmaceuticals.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here